Research Tracers
A clear path for the future
EXPAND
ACCELERATE
INNOVATE
www.ibamolecular.com
Molecular Imaging: A Clear Path
The future of molecular imaging is on the minds of many in the imaging community. Today’s
research is crucial to the future of molecular imaging, diagnostics and therapeutics. In this exciting
time of exploring new frontiers, the deployment of more targeted and impactful compounds is key
to winning the fight against disease. IBA Molecular has made a strong commitment to supporting
the research and development of these new products. With many years of collective experience in
producing F-18-labelled and other radiopharmaceutical compounds, we are continuing to expand
our research tracer offerings to support programs at leading institutions. Creating a clear path for
research and development is crucial and the choices made today can lead to an active commitment
to the future of molecular imaging.
IBA Molecular is uniquely positioned to:
EXPAND
Maximize worldwide access to a
wide range of novel radioisotopes
and compounds
ACCELERATE
Utilize our expertise, innovation
and experience to focus and
accelerate research efforts
INNOVATE
Align with key biopharma entities
to develop new compounds and
access to clinical trials
The Next Generation of Molecular Imaging
Ga-68 DOTATOC CASE STUDY
Whole body “one-stop shop” diagnosis with receptor-PET/CT
(A - MIP; B, C and D - PET, CT and fused images) using Ga-68
DOTATOC showing primary neuroendocrine tumor in the ileum (B)
with lymph node (C) & bone metastases (D).
Study and images source: Theranostics 2012; 2(5):437-447. doi:10.7150/thno.3645
IBA Molecular is providing the next generation
of molecular imaging products and services
to research programs worldwide. We provide
radiolabeling and development services, as
well as manufacturing of clinical trial and
commercial doses for promising diagnostic
and therapeutic isotopes. By aligning with
academic institutions, biotechnology and
pharmaceutical companies, we will work with
our partners to validate the ongoing unmet
medical needs as well as the potential impact
of these products on disease management.
Our objective is to facilitate research,
development and commercialization of the
next generation of molecular imaging and
therapeutic products, which is expected to
provide targeted improvements in patient care
and outcomes
181,000
The number of registered
studies has grown 1500%
in 10 yrs*
$100 B
Capital investment spent
on research in the last
10 yrs*
1
Goal. To deliver the
next generation of
targeted agents
Research Tracers
Ga-68 DOTATOC/TATE (DOTATOC Under DMF)
Radiolabeled somatostatin analogs being investigated for the
diagnosis and treatment of neuroendocrine tumors (NETs).
Ga-68 Chloride and Citrate
For use in labeling peptides and antibodies such as PSMA.
F-18 Bulk
For use in synthesis of multiple F-18 based tracers.
F-18 FLT Fluorothymidine
Thymidine analog which targets cell proliferation, currently being
studied for response to therapy in lymphoma, breast, head
and neck, brain, cervical, pancreatic, esophageal, kidney, lung,
colorectal and neuroendocrine cancers.
F-18 FLT IN RESPONSE TO THERAPY
Highest purity I-124 (sole DMF in U.S.)
Being used in a variety of PET applications, including protein and
antibody iodinations, and in the design of new PET tracers. Also
being used to develop novel therapies using large biomolecules
and nanoparticles.
Zr-89 Zirconium
Zr-89 Zirconium is used in PET imaging with radiolabeled
monoclonal antibodies. Zr-89-based PET imaging has been
investigated for a wide variety of cancer-related targets.
Ac-225 Actimab-A**
Monoclonal antibody-directed alpha emitter drug candidate under
development for the front line treatment of newly diagnosed
elderly acute myeloid leukemia patients.
I-131- Iomab-B**
Monoclonal antibody under development that targets CD45, an
antigen associated with acute myeloid leukemia. Also shows utility
in other indications, including myelodysplasia syndrome, acute
lymphoblastic leukemia, Hodgkin’s disease and Non-Hodgkin
Lymphoma.
Zr-89 PSMA**
An immunoPET tracer for imaging prostate cancer, IAB2m is
a monoclonal antibody fragment targeting prostate-specific
membrane antigen (PSMA).
Breast FLT PET-CT SUVmax reduction >39% pretreatment
(lower row) compared with 10 days after start of the first cycle of
chemotherapy (upper row). Drawn circles indicate lesion position
on respective PET slices containing SUVmax. FLT = 3-Deoxy-318F-fluorothymidine, PET = positron emission tomography, CT =
computed tomography, SUV = standardized uptake value, max =
maximum
Study and images source: Indian J Nucl Med. 2014 Apr-Jun; 29(2): 65–73.
F-18 Tau**
Imaging agent under development to identify tau neurofibrillary
tangles in the characterization of cognitive impairment, including
Alzheimer’s disease.
* Source: http://clinicaltrials.gov
** Proprietary compound
Clinical Trial Use - Clinical trial use of certain products should include the
appropriate filing of an investigator-sponsored Investigational New Drug (IND)
application to the FDA.
Where applicable, IBA Molecular may supply a Letter of Authorization to permit
cross-reference to its Drug Master File for the specific product.
Access to Clinical Trials
IBA Molecular has partnered with key biopharma companies to develop new compounds for clinical
trials. Your qualification and selection in clinical trials may optimize the use of your imaging equipment
and staff expertise as well as potentially being included in published outcomes.
IBA Molecular
IBA Molecular is a global developer, manufacturer and distributor
of radiopharmaceutical products and supporting services used in
molecular imaging. We have engineered a strong and unique product
portfolio of diagnostic and therapeutic tracers. We also provide
educational content, technical, research and marketing support to
medical specialists worldwide to help better respond to patient needs.
Contact Us
IBA Molecular North America, Inc.
21000 Atlantic Blvd., Suite 730
Dulles, VA 20166
Toll Free: 1 877 334 3673
Tel.: + 1 703 787 7900
Fax.: + 1 571 434 0330
IBA Molecular North America | January 2015 | Research Tracers © IBA 2015/All Rights Reserved.
For additional information regarding technical specifications, availability, pricing and ordering
of these and other products please contact us at marketingus@ibamolecular.com
www.ibamolecular.com